Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Resverlogix Corp. T.RVX

Alternate Symbol(s):  T.RVX.W.A | RVXCF

Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.


Recent & Breaking News (TSX:RVX)

Apabetalone’s beneficial effects on COVID-19 patients published in a prestigious scientific journal

Trevor Abes  March 17, 2021

Apabetalone's Beneficial Effects on COVID-19 Published in Prestigious Scientific Journal Cell

GlobeNewswire March 17, 2021

Resverlogix (TSX:RVX) apabetalone treatment prevents COVID-19 in human lung cells

Trevor Abes  March 15, 2021

Apabetalone Treatment Prevents COVID-19 Infection of Human Lung Cells

GlobeNewswire March 15, 2021

Zenith Epigenetics Announces Dosing of First mCRPC Patient with a Combination of ZEN-3694 + Merck's Immune Check Point Inhibitor KEYTRUDA

GlobeNewswire March 15, 2021

Resverlogix Announces Change in Fiscal Year-End to December 31

GlobeNewswire March 12, 2021

New Published Evidence of Apabetalone's Beneficial Effects on COVID-19

GlobeNewswire March 3, 2021

Resverlogix Reschedules Update Webcast and Conference Call

GlobeNewswire January 27, 2021

Resverlogix Announces Update Webcast and Conference Call

GlobeNewswire January 18, 2021

Publication finds Resverlogix (TSX:RVX) publishes positive Apabetalone results

Isabella Zavarise January 14, 2021

Apabetalone's Positive Effect on Hospitalized Patients Involving Heart Failure

GlobeNewswire January 12, 2021

Resverlogix (TSX:RVX) posts promising COVID-19 treatment findings

Isabella Zavarise December 23, 2020

Resverlogix Announces Voting Results from the 2020 Meeting of Shareholders and Update on $13 Million Investment by Sheikh Abdulgader Aboud Baeshen

GlobeNewswire December 22, 2020

Resverlogix Announces Apabetalone Treatment Prior to SARS-CoV-2 (COVID-19) Exposure Significantly Reduces Viral Infection - Confirms Plans for COVID-19 Clinical Trial

GlobeNewswire December 22, 2020

Resverlogix Files Notice of Annual and Special Meeting of Shareholders

GlobeNewswire November 20, 2020

Zenith Files Notice of Annual and Special Meeting of Shareholders

GlobeNewswire November 20, 2020

Resverlogix Announces Publication in High-impact, Peer-reviewed Journal, Clinical Epigenetics

GlobeNewswire November 12, 2020

Resverlogix Reports Filing of New Intellectual Property on Key Renal Protection and Glucose Control Markers

GlobeNewswire November 2, 2020

Zenith Confirms Interim Filings on SEDAR

GlobeNewswire October 28, 2020

A Second Publication Shortlists Resverlogix Clinical Candidate Apabetalone for its Potential COVID-19 Effectiveness Including Reducing Cytokine Storms

GlobeNewswire October 26, 2020